Metastatic Prostate Cancer Treatment: Xtandi Vs. Zytiga
Xtandi (enzalutamide) and Zytiga (abiraterone acetate) are FDA-approved treatments for metastatic castration-resistant prostate cancer (CRPC). Both drugs work by blocking the effects of androgens on prostate cancer cells. Studies have demonstrated their effectiveness in improving survival and progression-free survival. Common side effects include fatigue, diarrhea, nausea, dizziness, and electrolyte imbalances. The cost of treatment is…